WA
The startup has developed a vivo gene delivery platform that utilizes a targeting polymeric nanoparticle combined with a lentiviral vector to enhance transduction efficiency in quiescent T-cells, NK cells, and stem cells. This technology addresses the challenge of low transduction rates in these cells, enabling researchers to achieve more effective gene delivery for therapeutic applications.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a vivo gene delivery platform that utilizes a targeting polymeric nanoparticle combined with a lentiviral vector to enhance transduction efficiency in quiescent T-cells, NK cells, and stem cells. This technology addresses the challenge of low transduction rates in these cells, enabling researchers to achieve more effective gene delivery for therapeutic applications.